.Attribute Medicine, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view asks for addition of patients along with MASLD and also size of liver outcomes in cardio-- renal-- metabolic trials, when data recommend mechanistically plausible benefits and also scientific safety and security-- and also describes considerations for trial layout and also regulatory commendation.